Following its successful launch in India last year, we have now launched the drug-free migraine management device Nerivio® in Germany through our step-down subsidiary betapharm.
In 2023, we presented Nerivio® at the DGN Kongress organised by the German Association of Neurology in Berlin, and the 17th European Headache Congress held in Barcelona, Spain. We will present and launch Nerivio® during the Neurological Association of South Africa annual congress on April 17, 2024. In subsequent months, we will launch Nerivio® in Spain and the UK.
Nerivio® is a USFDA-approved and CE-mark certified drug-free wearable device that uses Remote Electrical Neuromodulation (REN) mechanism for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years).
We launched Nerivio® in India in 2023, where it is the first USFDA-approved REN device. In India, Nerivio® is backed by our comprehensive patient support programme called ‘M-Free’ for complete migraine care.
Migraine is a global health challenge. As conversations on migraine focus on migraine as a women’s health issue, relief through the use of technology and drug-free solutions, challenges associated with managing migraine during the child-bearing age, and distinguishing migraine from headache, Nerivio® and its Remote Electrical Neuromodulation (REN) technology have been recommended by neurologists across India and brought relief to patients living with migraine.
For more details, please visit: https://bit.ly/49C0YJr
[Nerivio® is a prescription-based product. Patients are advised to consult their neurologists on the use of the device and management of migraine. For more queries, doctors and patients can call the dedicated helpline number 1800-123-2360 (toll-free) or email us at [email protected] or WhatsApp on 6366881900.]
